The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Doxorubicin-Induced Cardiomyopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
Wyllie, A. H. (1980) · Nature · doi:10.1038/284555a0 · Cited by 4,504
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., & Nagata, S. (1998) · Nature · doi:10.1038/34112 · Cited by 3,189
Koopman, G., Reutelingsperger, C., Kuijten, G., Keehnen, R., Pals, S., & van Oers, M. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,681
Chinnaiyan, A. M., O'Rourke, K., Tewari, M., & Dixit, V. M. (1995) · Cell · doi:10.1016/0092-8674(95)90071-3 · Cited by 2,431
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Ichijo, H., Nishida, E., Irie, K., Dijke, P. T., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., & Gotoh, Y. (1997) · Science · doi:10.1126/science.275.5296.90 · Cited by 2,307
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Regulating the fate of mRNA: the control of cellular iron metabolism
Klausner, R. D., Rouault, T. A., & Harford, J. B. (1993) · Cell · doi:10.1016/0092-8674(93)90046-s · Cited by 1,210
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Reactions of oxyl radicals with DNA
Breen, A. P., & Murphy, J. A. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00209-3 · Cited by 1,038
Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the Human
Burnett, J. C., Kao, P. C., Hu, D. C., Heser, D. W., Heublein, D., Granger, J. P., Opgenorth, T. J., & Reeder, G. S. (1986) · Science · doi:10.1126/science.2935937 · Cited by 891
Apoptosis: Basic Mechanisms and Implications for Cardiovascular Disease
Haunstetter, A., & Izumo, S. (1998) · Circulation Research · doi:10.1161/01.res.82.11.1111 · Cited by 807
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Carson, D. A., & Ribeiro, J. M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91154-e · Cited by 680
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Narula, J., Pandey, P., Arbustini, E., Haider, N., Narula, N., Kolodgie, F. D., Dal Bello, B., Semigran, M. J., Bielsa-Masdeu, A., Dec, G. W., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8144 · Cited by 585
Programmed Cell Death in the Immune System
Cohen, J. J. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60822-6 · Cited by 560
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558
JNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins
Tsuruta, F., Sunayama, J., Mori, Y., Hattori, S., Shimizu, S., Tsujimoto, Y., Yoshioka, K., Masuyama, N., & Gotoh, Y. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600194 · Cited by 556
In vivo detection and imaging of phosphatidylserine expression during programmed cell death
Blankenberg, F. G., Katsikis, P. D., Tait, J. F., Davis, R. E., Naumovski, L., Ohtsuki, K., Kopiwoda, S., Abrams, M. J., Darkes, M., Robbins, R. C., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6349 · Cited by 536
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., McKenzie, W. B., Alexander, J., Sager, P., D'Souza, A., Manatunga, A., Schwartz, P. E., Berger, H. J., Setaro, J., Surkin, L., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 510
Apoptosis and Heart Failure: A Critical Review of the Literature
Kang, P. M., & Izumo, S. (2000) · Circulation Research · doi:10.1161/01.res.86.11.1107 · Cited by 506
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.
Bachur, N. R., Gordon, S. L., Gee, M. V., & Kon, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.2.954 · Cited by 489
Subcellular effects of adriamycin in the heart: A concise review
SINGAL, P., DEALLY, C., & WEINBERG, L. (1987) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(87)80392-9 · Cited by 465
Daunomycin-induced cardiotoxicity in children and adults
Von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., & Muggia, F. M. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90315-1 · Cited by 437
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Kotamraju, S., Konorev, E. A., Joseph, J., & Kalyanaraman, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003890200 · Cited by 372
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366
Death by Design: Programmed Cell Death in Cardiovascular Biology and Disease
MacLellan, W. R., & Schneider, M. D. (1997) · Circulation Research · doi:10.1161/01.res.81.2.137 · Cited by 358
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Koseki, T., Inohara, N., Chen, S., & Núñez, G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5156 · Cited by 347
FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis
Srinivasula, S. M., Ahmad, M., Ottilie, S., Bullrich, F., Banks, S., Wang, Y., Fernandes-Alnemri, T., Croce, C. M., Litwack, G., Tomaselli, K. J., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18542 · Cited by 335
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334
Rapid responses to oxidative stress mediated by iron regulatory protein.
Pantopoulos, K., & Hentze, M. W. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07291.x · Cited by 328
Kanoh, M., Takemura, G., Misao, J., Hayakawa, Y., Aoyama, T., Nishigaki, K., Noda, T., Fujiwara, T., Fukuda, K., Minatoguchi, S., et al. (1999) · Circulation · doi:10.1161/01.cir.99.21.2757 · Cited by 320
Self-citationKalyanaraman, B., Perez-Reyes, E., & Mason, R. P. (1980) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(80)90142-7 · Cited by 317
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Molkentin, J. D., Kalvakolanu, D. V., & Markham, B. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4947 · Cited by 309
DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage.
Holm, C., Stearns, T., & Botstein, D. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.1.159 · Cited by 307
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., & Nemer, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401833101 · Cited by 296
Doxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Oxygen/Nitrogen Radicals: Cell Injury and Disease · doi:10.1007/978-1-4615-1087-1_13 · Cited by 296
Doxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1015976430790 · Cited by 293
Losing heart: the role of apoptosis in heart disease—a novel therapeutic target?
Gill, C., Mestril, R., & Samali, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0629com · Cited by 289
Increased Human Brain Natriuretic Peptide in Congestive Heart Failure
(1990) · New England Journal of Medicine · doi:10.1056/nejm199009133231114 · Cited by 287
Regulation of Cardiomyocyte Apoptotic Signaling by Insulin-like Growth Factor I
Wang, L., Ma, W., Markovich, R., Chen, J.-W., & Wang, P. H. (1998) · Circulation Research · doi:10.1161/01.res.83.5.516 · Cited by 287
Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995) · Circulation · doi:10.1161/01.cir.91.1.10 · Cited by 285
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, E., Ungvári, Z., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
Berlin, V., & Haseltine, W. A. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69315-4 · Cited by 275
Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.6.2829 · Cited by 265
Schuchter, L. M., Hensley, M. L., Meropol, N. J., & Winer, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.178 · Cited by 262
Antioxidants and Cancer Therapy: A Systematic Review
Ladas, E. J., Jacobson, J. S., Kennedy, D. D., Teel, K., Fleischauer, A., & Kelly, K. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.086 · Cited by 260
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Dose-effect and structure-function relationships in doxorubicin cardiomyopathy
Bristow, M. R., Mason, J. W., Billingham, M. E., & Daniels, J. R. (1981) · American Heart Journal · doi:10.1016/0002-8703(81)90096-x · Cited by 245
Iron-sulfur clusters as biosensors of oxidants and iron.
Rouault, T. A., & Klausner, R. D. (1996) · PubMed · Cited by 238
Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.
Olson, H. M., Young, D. M., Prieur, D. J., LeRoy, A. F., & Reagan, R. L. (1974) · PubMed Central · Cited by 237
Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39082-2 · Cited by 229
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Kalivendi, S. V., Kotamraju, S., Zhao, H., Joseph, J., & Kalyanaraman, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106829200 · Cited by 225
Fulda, S., Meyer, E., Friesen, C., Susin, S. A., Kroemer, G., & Debatin, K.-M. (2001) · Oncogene · doi:10.1038/sj.onc.1204141 · Cited by 223
TORTI, F. M., BRISTOW, M. R., HOWES, A. E., ASTON, D., STOCKDALE, F. E., CARTER, S. K., KOHLER, M., BROWN, B. W., & BILLINGHAM, M. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-745 · Cited by 215
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
MINOTTI, G., CAIRO, G., & MONTI, E. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.2.199 · Cited by 214
Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., & Myers, C. E. (1987) · Biochemistry · doi:10.1021/bi00387a006 · Cited by 214
Daunorubicin-Induced Apoptosis in Rat Cardiac Myocytes Is Inhibited by Dexrazoxane
Sawyer, D. B., Fukazawa, R., Arstall, M. A., & Kelly, R. A. (1999) · Circulation Research · doi:10.1161/01.res.84.3.257 · Cited by 207
Iron-sulfur clusters as biosensors of oxidants and iron
Rouault, T. A., & Klausner, R. D. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10024-4 · Cited by 206
Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy
Li, L., Takemura, G., Li, Y., Miyata, S., Esaki, M., Okada, H., Kanamori, H., Khai, N. C., Maruyama, R., Ogino, A., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568402 · Cited by 197
Self-citationAdriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells
Skladanowski, A., & Konopa, J. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90512-u · Cited by 189
Didenko, V. V., & Hornsby, P. J. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.5.1369 · Cited by 189
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., & Suzuki, Y. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.368 · Cited by 188
Elevated B-type natriuretic peptide levels after anthracycline administration
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., Kurabayashi, M., Yamaoki, K., Mitani, K., Hirai, H., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89908 · Cited by 185
Mason, J. W., Bristow, M. R., Billingham, M. E., & Daniels, J. R. (1978) · PubMed · Cited by 175
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Vanadate Induces p53 Transactivation through Hydrogen Peroxide and Causes Apoptosis
Huang, C., Zhang, Z., Ding, M., Li, J., Ye, J., Leonard, S. S., Shen, H.-M., Butterworth, L., Lu, Y., Costa, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005366200 · Cited by 173
Oxidative destruction of DNA by the adriamycin-iron complex
Eliot, H., Gianni, L., & Myers, C. (1984) · Biochemistry · doi:10.1021/bi00300a021 · Cited by 172
The cardiotoxicity of adriamycin and daunomycin in children
Gilladoga, A. C., Manuel, C., Tan, C. T. C., Wollner, N., Sternberg, S. S., & Murphy, M. L. (1976) · Cancer · doi:10.1002/1097-0142(197602)37:2+<1070::aid-cncr2820370814>3.0.co;2-6 · Cited by 171
Bristow, M. R., Sageman, W. S., Scott, R. H., Billingham, M. E., Bowden, R. E., Kernoff, R. S., Snidow, G. H., & Daniels, J. R. (1980) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198009000-00002 · Cited by 171
Vleet, J. F. V., Ferrans, V. J., & Weirich, W. E. (1980) · PubMed · Cited by 169
Apoptosis in relevant clinical situations contribution of apoptosis in myocardial infarction
Yaoita, H. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00349-1 · Cited by 168
Pantopoulos, K., Mueller, S., Atzberger, A., Ansorge, W., Stremmel, W., & Hentze, M. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.9802 · Cited by 163
Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy
Ganz, W. I., Sridhar, K. S., Ganz, S. S., Gonzalez, R. R., Chakko, S. C., & Serafini, A. N. (2009) · Oncology · doi:10.1159/000227621 · Cited by 151
Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex
Muindi, J. R., Sinha, B. K., Gianni, L., & Myers, C. E. (1984) · FEBS Letters · doi:10.1016/0014-5793(84)81130-8 · Cited by 150
Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin.
Olson, R. D., MacDonald, J. S., VanBoxtel, C. J., Boerth, R. C., Harbison, R. D., Slonim, A. E., Freeman, R. W., & Oates, J. A. (1980) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32319-0 · Cited by 147
Oxidative Stress Induces Activation of a Cytosolic Protein Responsible for Control of Iron Uptake
Martins, E. A. L., Robalinho, R. L., & Meneghini, R. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1019 · Cited by 146
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
McKillop, J. H., Bristow, M. R., Goris, M. L., Billingham, M. E., & Bockemuehl, K. (1983) · American Heart Journal · doi:10.1016/0002-8703(83)90651-8 · Cited by 144
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
Alberts, D. S., Muggia, F. M., Carmichael, J., Winer, E. P., Jahanzeb, M., Venook, A. P., Skubitz, K. M., Rivera, E., Sparano, J. A., DiBella, N. J., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.010 · Cited by 139
Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity
Seifert, C. F., Nesser, M. E., & Thompson, D. F. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800912 · Cited by 139
Doxorubicin-induced cardiomyopathy
(1984) · Reactions Weekly · doi:10.1007/bf03273255 · Cited by 139
Elsässer, A., Suzuki, K., & Schaper, J. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1125 · Cited by 138
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy
Singal, P. K. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(95)90074-8 · Cited by 131
Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., & Sakurai, M. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1155 · Cited by 130
Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes
Sarvazyan, N. A. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.271.5.h2079 · Cited by 127
Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II Study
Treat, J., Greenspan, A., Forst, D. A., Sanchez, J., Ferrans, V. J., Potkul, L., Woolley, P. V., & Rahman, A. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.21.1706 · Cited by 123
The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation
Wang, S., Leonard, S. S., Ye, J., Ding, M., & Shi, X. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.3.c868 · Cited by 123
Green, D. M., Hyland, A. J., Chung, C. S., Zevon, M. A., & Hall, B. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3207 · Cited by 121
Zhang, J. H. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0186 · Cited by 120
Herman, E., Ferrans, V. J., Myers, C. E., & Vleet, J. F. V. (1985) · PubMed · Cited by 120
Konorev, E. A., Kennedy, M. C., & Kalyanaraman, B. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1337 · Cited by 118
Feuerstein, G., Yue, T., Ma, X., & Ruffolo, R. R., Jr. (1998) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(98)80027-3 · Cited by 116
Mihm, M. J., Yu, F., Weinstein, D. M., Reiser, P. J., & Bauer, J. A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704495 · Cited by 115
Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy
Lou, H., Danelisen, I., & Singal, P. K. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01054.2004 · Cited by 115
Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner, A. P., Paine, M. J. I., Rodríguez‐Crespo, I., Chinje, E. C., de Montellano, P. R. O., Stratford, I. J., Tew, D. G., & Wolf, C. R. (1999) · PubMed · Cited by 110
Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells
Sinha, B. K., Katki, A. G., Batist, G., Cowan, K. H., & Myers, C. E. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90164-x · Cited by 109
Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats
Tong, J., Ganguly, P. K., & Singal, P. K. (1991) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1991.260.3.h909 · Cited by 109
Herman, E. H., & Ferrans, V. J. (1981) · PubMed · Cited by 108
Narula, J., Kolodgie, F. D., & Virmani, R. (2000) · Current Opinion in Cardiology · doi:10.1097/00001573-200005000-00011 · Cited by 108
Ascorbic acid and adriamycin toxicity
Shimpo, K., Nagatsu, T., Yamada, K., Sato, T., Niimi, H., Shamoto, M., Takeuchi, T., Umezawa, H., & Fujita, K. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.6.1298s · Cited by 106
Singal, P. K., & Pierce, G. N. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.3.h419 · Cited by 105
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats
Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., & Hayakawa, T. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00362-8 · Cited by 103
Morphological aspects of apoptosis in heart diseases
Takemura, G., & Fujiwara, H. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00291.x · Cited by 99
Self-citationDoxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy
Bielack, S., Erttmann, R., Winkler, K., & Landbeck, G. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90135-1 · Cited by 94
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin
Bristow, M. R., Lopez, M. B., Mason, J. W., Billingham, M. E., & Winchester, M. A. (1982) · Cancer · Cited by 92
Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4
Murphy, A. M., Thompson, W. R., Ling Fan, P. E. N. G., & Jones, L. (1997) · Biochemical Journal · doi:10.1042/bj3220393 · Cited by 91
Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
Bennink, R. J., van den Hoff, M. J. B., van Hemert, F. J., de Bruin, K. M., Spijkerboer, A. L., Vanderheyden, J., Steinmetz, N. D., & van Eck‐Smit, B. L. F. (2004) · PubMed · Cited by 85
Morandi, P., Ruffini, P., Benvenuto, G., Vecchia, L. L., Mezzena, G., & Raimondi, R. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703132 · Cited by 84
Biochemical determinants of adriamycin® toxicity in mouse liver, heart and intestine
Odom, A., Hatwig, C. A., Stanley, J. S., & Benson, A. M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90250-m · Cited by 76
Tokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.516 · Cited by 75
Gehring, N. H., Hentze, M. W., & Pantopoulos, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6219 · Cited by 71
Early changes in myocardial antioxidant enzymes in rats treated with adriamycin
Li, T., Danelisen, I., & Singal, P. K. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1014862912783 · Cited by 69
Intervention of adriamycin induced free radical damage.
Balanehru, S., & Nagarajan, B. (1992) · PubMed · Cited by 68
The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice
Mimnaugh, E. G., Siddik, Z. H., Drew, R., Sikic, B. I., & Gram, T. E. (1979) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(79)90284-9 · Cited by 66
Free radical production from normal and adriamycin-treated rat cardiac sarcosomes
Thornalley, P. J., & Dodd, N. J. F. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90262-x · Cited by 61
Lanzarini, L. F., Bossi, G., Laudisa, M. L., Klersy, C., & Aricò, M. (2000) · American Heart Journal · doi:10.1067/mhj.2000.108237 · Cited by 60
Ibrahim, N. K., Hortobágyi, G. N., Ewer, M. S., Ali, M. K., Asmar, L., Theriault, R. L., Fraschini, G., Frye, D. K., & Buzdar, A. U. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050926 · Cited by 58
Monti, E., Prosperi, E., Supino, R., et al. (1995) · PubMed · Cited by 55
Speyer, J. L., Green, M. D., Dubin, N., Blum, R. H., Wernz, J., Roses, D. F., Sanger, J. J., & Muggia, F. M. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90395-x · Cited by 52
Apoptosis in cardiovascular disease.
Davies, M. J. (1997) · Heart · doi:10.1136/hrt.77.6.498 · Cited by 51
Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice
Nowak, D., Pierściński, G., & Drzewoski, J. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)00028-v · Cited by 50
Hou, X., Son, J. C., Wang, Y., Ru, Y. X., Lian, Q. Q., Majiti, W., Amazouzi, A., Zhou, Y. L., Wang, P. X., & Han, Z. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-7652-9 · Cited by 49
Phase I study of ICRF-187 using a daily for 3 days schedule.
Hoff, V., Howser, D. M., Bj, L., Holcenberg, J. S., Weiss, R. B., & Rc, Y. (1981) · PubMed · Cited by 45
Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells: a spin-trapping study
Alegría, A. E., Samuni, A. M., Mitchell, J. B., Riesz, P., & Russo, A. (1989) · Biochemistry · doi:10.1021/bi00447a056 · Cited by 40
Koda, M., Takemura, G., Kanoh, M., Hayakawa, K., Kawase, Y., Maruyama, R., Li, Y., Minatoguchi, S., Fujiwara, T., & Fujiwara, H. (2003) · The Journal of Pathology · doi:10.1002/path.1261 · Cited by 40
Self-citationCurran, C. F. (1991) · Cancer Treatment Reviews · doi:10.1016/0305-7372(91)90015-r · Cited by 37
Hughes, S. (2003) · The Journal of Pathology · doi:10.1002/path.1447 · Cited by 37
Measurement of the Quality of Life in End-Stage Renal Failure
Arico, M., Nespoli, L., Pedroni, E., Bonetti, F., Vigano, M., & Burgio, G. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811173192015 · Cited by 31
Vile, G. F., & Winterbourn, C. C. (1990) · PubMed · Cited by 30
New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity
El‐Demerdash, E., Ali, A. A., Sayed‐Ahmed, M. M., & Osman, A. M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0676-y · Cited by 29
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef, M. L., Synold, T. W., Chow, W. A., Leong, L., Margolin, K. A., Morgan, R. J., Raschko, J. W., Shibata, S., Somlo, G., Yen, Y., et al. (2001) · PubMed · Cited by 22
The Effect of Vitamin E and Selenium on Doxorubicin (Adriamycin®) Induced Delayed Toxicity in Mice
Hermansen, K., & Wassermann, K. (1986) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1986.tb00066.x · Cited by 20
Clinical role of indium-111 antimyosin imaging
Bhattacharya, S., & Lahiri, A. (1991) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf02258455 · Cited by 16
Direct detection of paramagnetic species in adriamycin perfused rat hearts
Costa, L. E., Malatesta, V., Morazzoni, F., Scotti, R., Monti, E., & Paracchini, L. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)81218-x · Cited by 11
Cited by
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Metadata
- Authors
- Takemura, G., & Fujiwara, H.
- Venue
- Progress in Cardiovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 49
- Issue
- 5
- Pages
- 330-352
- ISSN
- 0033-0620 (ISSN-L)
- OpenAlex
- W2162689981
- Cited by
- 827
- References
- 152
- FWCI
- 20.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.